Developed by Samsung Bioepis Co., Ltd., and commercialized by Sandoz, Pyzchiva® has been approved by the US Food and Drug Administration (FDA) for the treatment of certain chronic inflammatory ...

Sandoz initiated a transformation program to make its organization more agile, simpler and more efficient. The Company anticipates further major biosimilar launches in 2025, including Pyzchiva ...